No profile photo available

Jackson R. Richards, MD, PhD

Languages spoken: English

Academic Information

Departments Primary - Psychiatry

Divisions: Adult Psychiatry

Academic Office Information

jackson.richards@hsc.utah.edu

Jackson Richards, MD, PhD, Instructor (Clinical), is a board-eligible psychiatrist with expertise in inpatient and interventional psychiatry. He received his medical doctorate and graduate doctorate degrees from the University of Utah. He completed psychiatry residency training at the University of Iowa and is thrilled to return to Utah. Dr. Richards currently serves as an attending psychiatrist at the Huntsman Mental Health Institute’s Kem and Carolyn Gardner Mental Health Crisis Care Center. He will be involved in the expansion of the Treatment-Resistant Mood Disorders Clinic to this site and plans to participate in clinical trials. Dr. Richards also enjoys working with medical students and psychiatry residents.

Education History

Undergraduate University of Utah
 BS
Professional Medical University of Utah Spencer Fox Eccles School of Medicine
 PhD
Professional Medical University of Utah Spencer Fox Eccles School of Medicine
 MD
Residency University of Iowa Carver College of Medicine
 Resident

Selected Publications

Journal Article

  1. Wirthlin D, Richards Z, Crandall CS, Mortensen SP, Richards JR, Bakian AV (2024). The School Suicide Policy Evaluation Tool (SSPET): A proof-of-concept for assessing school suicide prevention policies. Public Health Chall, 3(2), e178.
  2. Richards JR, Shin D, Pryor R, Sorensen LK, Sun Z, So WM, Park G, Wolff R, Truong A, McMahon M, Grossmann AH, Harbour JW, Zhu W, Odelberg SJ, Yoo JH (2023). Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis. Oncogene, 42(35), 2629-2640.
  3. Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, Blumer KJ, Odelberg SJ, McMahon M (2020). Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition. Clin Cancer Res, 26(23), 6374-6386.
  4. Du GH, Wang JK, Richards JR, Wang JJ (2019). Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer. Int Immunopharmacol, 66, 154-161.
  5. Grossmann AH, Zhao H, Jenkins N, Zhu W, Richards JR, Yoo JH, Winter JM, Rich B, Mleynek TM, Li DY, Odelberg SJ (2019). The small GTPase ARF6 regulates protein trafficking to control cellular function during development and in disease. Small GTPases, 10(1), 1-12.
  6. Zhu W, Shi DS, Winter JM, Rich BE, Tong Z, Sorensen LK, Zhao H, Huang Y, Tai Z, Mleynek TM, Yoo JH, Dunn C, Ling J, Bergquist JA, Richards JR, Jiang A, Lesniewski LA, Hartnett ME, Ward DM, Mueller AL, Ostanin K, Thomas KR, Odelberg SJ, Li DY (2017). Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy. J Clin Invest, 127(12), 4569-4582.
  7. Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY (2016). ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell, 29(6), 889-904.
  8. Richards J, Korgenski EK, Srivastava R, Bonkowsky JL (2015). Costs of the diagnostic odyssey in children with inherited leukodystrophies. Neurology, 85(13), 1167-70.
  9. Richards J, Korgenski EK, Taft RJ, Vanderver A, Bonkowsky JL (2015). Targeted leukodystrophy diagnosis based on charges and yields for testing. Am J Med Genet A, 167A(11), 2541-3.
  10. Watanabe S, Lehmann M, Hujber E, Fetter RD, Richards J, S�hl-Kielczynski B, Felies A, Rosenmund C, Schmoranzer J, Jorgensen EM (2014). Nanometer-resolution fluorescence electron microscopy (nano-EM) in cultured cells. Methods Mol Biol, 1117, 503-26.

Review

  1. Trapp NT, Purgianto A, Taylor JJ, Singh MK, Oberman LM, Mickey BJ, Youssef NA, Solzbacher D, Zebley B, Cabrera LY, Conroy S, Cristancho M, Richards JR, Flood MJ, Barbour T, Blumberger DM, Taylor SF, Feifel D, Reti IM, McClintock SM, Lisanby SH, Husain MM, National Network of Depression Centers Neuromodulation Task Group (2025). Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. [Review]. Clin Neurophysiol, 170, 206-233.
  2. Richards JR, Yoo JH, Shin D, Odelberg SJ (2020). Mouse models of uveal melanoma: Strengths, weaknesses, and future directions. [Review]. Pigment Cell Melanoma Res, 33, (2), 264-278.

Letter

  1. Richards JR, Pace BD, Lynch AC, Weber AN, Bruss JE, Vaidya JG, Jawish R, Jones KG, Mickey BJ, Carnahan RM, Trapp NT (2025). Dual-target theta burst rTMS for the treatment of methamphetamine use disorder: An open-label pilot clinical trial. [Letter to the editor]. Brain Stimul, 18(6), 1952-1954.

Other

  1. Richards JR, Shin D, Pryor R, Sorensen LK, Sun Z, So WM, Park G, Wolff R, Truong A, McMahon M, Grossmann AH, Harbour JW, Zhu W, Odelberg SJ, Yoo JH (2023). Correction: Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis. Oncogene (42(40), p. 3015). England.

Video/Film/CD/Web/Podcast

  1. Watanabe S, Richards J, Hollopeter G, Hobson RJ, Davis WM, Jorgensen EM (2012). Nano-fEM: protein localization using photo-activated localization microscopy and electron microscopy. [J Vis Exp], United States.